Academic Highlights: New Developments in the Treatment of Alzheimer's Disease [CME]
J Clin Psychiatry 2009;70(2):281-290
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Click to enlarge page
First identified as a disease process in the early 1900s, today Alzheimer’s disease (AD) looms as a public health crisis. In 2000, an estimated 4.5 million persons in the United States had mild, moderate, or severe AD; this figure could grow to 13.2 million by 2050. Peter V. Rabins, MD, MPH, brought together a group of experts to discuss ways to better diagnose and more effectively treat this rapidly growing population.
As the population ages and survival rates increase for patients with AD, not only will the number of persons with the disease increase rapidly, said Neill Graff-Radford, MB BCh, FRCP, but also the age distribution of persons with AD will change.